论文部分内容阅读
采用免疫组织化学ＳＰ法检测４１ 例肾癌、１８ 例癌旁正常肾组织及５ 例正常肾组织中Ｐ１６ 蛋白的表达，以探讨Ｐ１６ 蛋白的表达与肾癌组织学类型、临床分期、病理分级及预后的关系。结果发现Ｐ１６ 蛋白在肾癌及正常肾组织中的阳性表达率分别为５８－５ ％ （２４／４１） 及９１－３％ （２１／２３） ，两组阳性表达差异具有显著性（χ２ ＝ ７－６０ ，Ｐ＜０－０５） ；Ｐ１６ 蛋白表达在肾透明细胞癌及颗粒细胞癌间无差异，随肾癌分级、分期升高而明显降低，Ⅰ级与Ⅱ、Ⅲ级比较阳性表达具有显著差异，低分期组（ Ⅰ、Ⅱ） 与高分期组（Ⅲ、Ⅳ）比较具有显著差异；Ｐ１６ 阳性表达组术后５ 年生存率明显高于阴性表达组。结果提示：Ｐ１６ 基因失活在肾癌的发生发展中起重要作用，Ｐ１６ 基因及蛋白的检测可作为肾癌的辅助诊断及预后判断的参考指标。
Immunohistochemical SP method was used to detect the expression of P16 protein in 41 cases of renal cell carcinoma, 18 cases of adjacent normal renal tissue and 5 cases of normal renal tissues. The expression of P16 protein was compared with histological type, clinical stage, pathology Grading and prognosis of the relationship. The positive rates of P16 protein in renal cell carcinoma and normal renal tissues were 58-5% (24/41) and 91-3% (21/23), respectively. There was significant difference between the two groups (χ2 = 7 -60, P <0-05). There was no difference in P16 protein between renal clear cell carcinoma and granulosa cell carcinoma, which was significantly decreased with the increase of stage and stage of renal cell carcinoma. The positive expression of P16 protein was significant Difference, low stage group (Ⅰ, Ⅱ) and high stage group (Ⅲ, Ⅳ) were significantly different; P16 positive expression group 5-year survival rate was significantly higher than the negative expression group. The results suggest that the inactivation of P16 gene plays an important role in the development of renal cell carcinoma. The detection of P16 gene and protein may serve as a reference for the diagnosis and prognosis of renal cell carcinoma.